A new study found that compared to those with BRCA2 mutations outside exon 11, those with exon 11 mutations had a lower breast cancer risk, higher risk for ER-negative breast cancer, and later age at diagnosis. These findings suggest that taking mutation type and location into account in cancer risk models may improve the ability to predict individualized breast cancer risks. Ultimately, this information could be used to guide care.
Akamandisa, et al. Ann Oncol. 2025;36(8):954-963. PMID: 40288678. Article available at: https://pubmed.ncbi.nlm.nih.gov/40288678/. Social media post available at: https://www.facebook.com/share/p/1AzV2gpmer/